Investor Relations
Developing Novel Therapies to Destroy Cancer
Filings & Shareholder Info

As of July 31, 2022, Briacell determined that it no longer qualified as a “foreign private issuer” as such term is defined in Rule 405 under the Securities Act. This means that, as of August 1, 2022, the Company has been required to comply with all of the periodic disclosure requirements of the Securities Exchange Act of 1934 applicable to U.S. domestic issuers, such as Forms 10-K, 10-Q and 8-K, rather than the forms the Company has filed with the Securities and Exchange Commission (“SEC”) in the past, as a foreign private issuer, such as Forms 40-F and 6-K. Accordingly, the Company is now required to prepare its financial statements filed with the SEC in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).

AGM 2024
Report on Voting Results
Jan 30, 2024
Jan 9, 2024
BriaCell Notice Circular
Jan 9, 2024
BriaCell VIF
Jan 9, 2024
BriaCell Proxy
Jan 9, 2024
SEDAR+ Filings
Annual MDA
Annual FS
BriaCell Annual 10K
For additional SEDAR Filings, please visit
Shareholder Info
Computershare Investor Services
100 University Ave., 8th Floor, North Tower
Toronto, ON M5J 2Y1, Canada
Tel: 1-800-564-6253 (toll free in Canada & the US)
514-982-7555 (international direct dial)

Fax: 1-888-453-0330
BriaCell Therapeutics Corp. Common Shares
CUSIP: 107930109
ISIN: CA1079301091

BriaPro Therapeutics Common Shares (privately held)
ISIN: CA1079311074

CUSIP Number: 107930109
ISIN: CA1079301091
Corporate Office- Canada

Suite 300 - Bellevue Centre, 235 -15th Street,
West Vancouver, BC V7T 2X1

Tel: 604-921-1810
Fax: 604-921-1898

Corporate Office- US

2929 Arch Street, 3rd Floor
Philadelphia, PA 19104

Tel: 1-888-485-6340
Fax: 424-245-3719
Copyright 2024 © Briacell.| All rights reserved | XML Sitemap | HTML Sitemap